NCT00184561View on ClinicalTrials.gov

Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart

Trial Locations (8)

100029

Novo Nordisk Investigational Site, Beijing

100730

Novo Nordisk Investigational Site, Beijing

200003

Novo Nordisk Investigational Site, Shanghai

210008

Novo Nordisk Investigational Site, Nanjing

300070

Novo Nordisk Investigational Site, Tianjin

430022

Novo Nordisk Investigational Site, Wuhan

510120

Novo Nordisk Investigational Site, Guangzhou

710032

Novo Nordisk Investigational Site, Xi'an

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00184561 - Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter